Advertisement

Topics

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

2014-08-27 03:58:14 | BioPortfolio

Summary

OBJECTIVES:

I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available.

Description

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive intravenous acetylcysteine or placebo for 72 hours. Treatment must begin within 12 hours of hospitalization. Patients who advance to grade III or IV encephalopathy are eligible for liver transplantation.

Patients are followed at 3 weeks.

Study Design

Allocation: Randomized, Control: Placebo Control, Masking: Double-Blind, Primary Purpose: Treatment

Conditions

Acute Liver Failure

Intervention

acetylcysteine

Location

University of Alabama at Birmingham
Birmingham
Alabama
United States
35294-0005

Status

Completed

Source

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:58:14-0400

Clinical Trials [2879 Associated Clinical Trials listed on BioPortfolio]

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with ALF.

A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.

We have completed patient enrollment in the the double blind, randomized, placebo-controlled trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of non-acetamino...

Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury

Intervention - Subjects will be randomized to 2 groups Group A - subjects will receive Prednisolone for 20 days with NAC (N-Acetylcysteine) Group B - will receive NAC (N-Acetylcysteine) ...

Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose

Paracetamol (PCM) is a widely used over-the-counter analgesic, and overdose with PCM is a condition regularly seen in everyday clinical practice. Identification of the patients with early ...

A Multi-Center Trial to Study Acute Liver Failure in Adults

The purpose of this study is to collect clinical and epidemiological data as well as serum, plasma, urine, tissue and DNA samples on individuals who have acute liver failure and on individ...

PubMed Articles [12685 Associated PubMed Articles listed on BioPortfolio]

How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.

The definition of acute liver failure (ALF) usually implies no previous liver injury. Though, some patients admitted to liver transplantation centers with the diagnosis of ALF are obese or have diabet...

Dynamic Prognostication in Critically Ill Cirrhotic Patients With Multiorgan Failure in ICUs in Europe and North America: A Multicenter Analysis.

To evaluate the Chronic Liver Failure-Consortium Acute on Chronic Liver Failure score in acute on chronic liver failure patients admitted to ICUs from different global regions and compare discriminati...

Bioinformatic analysis of differentially expressed genes involved in the hepatitis B virus-associated acute liver failure.

The rarity of acute liver failure, along with its severity and heterogeneity, has resulted in a very limited evidence to understand of the molecular mechanism. To analyze the differentially expressed ...

SOFA in the first 24 hours as an outcome predictor of acute liver failure.

To describe a cohort of patients with acute liver failure and to analyze the demographic and clinical factors associated with mortality.

Auxiliary partial orthotopic liver transplantation for non-cirrhotic metabolic liver disease: Reigniting interest in an old but new technique.

Auxiliary partial orthotopic liver transplantation (APOLT) was initially explored for potentially reversible acute liver failure and noncirrhotic metabolic liver disease (NCMLD)(1, 2). The rationale f...

Medical and Biotech [MESH] Definitions

Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.

A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.

A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.

A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.

A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal failure, either acute (KIDNEY FAILURE, ACUTE) or chronic (KIDNEY FAILURE, CHRONIC), requires HEMODIALYSIS.

More From BioPortfolio on "Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial